PCI in Patients With Diabetes: Show Me the Data

Slides:

Advertisements

Similar presentations

In Diabetics with Ischemic Heart Disease CABG revascularization is always superior? Dr. Paolo Ferrazzi.

Advertisements

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

TITLE lecturer Institution. Presenter Disclosure Information.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,

Jose M. de la Torre Hernández … in behalf of the 3D investigators

Figure 1 Flow diagram of systematic review

Harvard Clinical Research Institute, Boston, US

Disclosures Speaker’s bureau: Research support: Consulting: Equity

Clinical value of post–percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis Goran Rimac, MD, William.

Addressing the Challenges in Primary and Secondary Stroke Prevention

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

DES Should be Used as the Default Stent in ACS!

Hospital admissions per patient, by modality figure 5

The RESOLUTE Program: today and tomorrow

On behalf of J. Belardi, M. Leon, L. Mauri,

Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.

European and US Guidelines

The Latest Lipid Guidelines:

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Trends in Coronary Procedures per 1000 Medicare Beneficiaries

Circ Cardiovasc Interv

New Guidelines to Prevent SCD: What You Need to Know

NOACs for Cancer-Associated Thrombosis:

Current Dyslipidemia Management Guidelines Residual Risk.

Diabetes and Risk of CV Outcomes

Atrial Fibrillation and PCI

Statin Selection Aimed to Reduce New-Onset DM Risk:

Cardiogenic Shock.

Complex Revascularization: Geographic Variations in Practice

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Selecting NOACs for High-Risk Patients

Terms of Use. Terms of Use.

Statin Class in Session

Considerations for Percutaneous Coronary Intervention (PCI)

Statin Class in Session

Efficacy and Safety of Edoxaban in Patients With AF and HF

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

AF and PCI in Practice.

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

Radical New Concepts in Lipid Management

Using Heart Rate as a Biomarker in Clinical Practice.

3-Year Clinical Outcomes From the RESOLUTE US Study

ENDEAVOR IV: 5 Year Final Outcomes

Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea

Aspirin and Cardioprevention in 2018

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Statins, Obesity, and Hyperlipidemia

Gregg W. Stone, MD Columbia University Medical Center

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

New Lipid-Lowering Guidelines

ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS

Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.

Long Term Clinical Results from the Endeavor Program: 5-Year Follow up

Maintenance of Long-Term Clinical Benefit with

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

Coronary Artery Bypass Revascularization Using Bilateral Internal Thoracic Arteries in Diabetic Patients: A Systematic Review and Meta-Analysis Kan Kajimoto,

Primary safety endpoint

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

Evaluating the Science of Cardiogenic Shock

Statin Therapy in Patients With Insulin Resistance

Lipids, the Heart, and the Kidney

Antithrombotic Therapy in AF Patients Undergoing PCI

Translating Data From Trial to Practice

Presentation transcript:

PCI in Patients With Diabetes: Show Me the Data

SYNTAX: Baseline Characteristics by Diabetes Status

Case 1: History and Presentation

Case 1: Cardiac Catheterization

ACCF/AHA/SCAI Guidelines on PCI: FFR

RESET: TLR at 1 Year

Is Sirolimus Less Effective in Diabetic Conditions?

Network Meta-analysis: EES Lower Risk of Stent Thrombosis vs BMS

Rates of Deep Sternal Infection After Bilateral IMA

Maze Procedure With CABG/AVR

Case 2 History and Presentation

Europeana and USb Guidelines: The Heart Team

RESOLUTE Pooled Patient Level Analysis R-ZES in Non-DM (n = 3595), NIDDM (n = 1080) and IDDM (n = 455)

Take-Home Points

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)